Mineralys Therapeutics, Inc. presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2-5. In this new analysis, investigators identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure (BP) of 32 millimeters of mercury (mmHg). Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.52 USD | -5.26% | +4.40% | +57.21% |
May. 09 | Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.21% | 671M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.56% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting